Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sorry. Miriam Kidron is a pharmacologist and a biochemist and I know absolutely nothing about her nor about the company.
Oral Insulin will be a big hit but I can not find info about these guys.
My bad, apparently there are 16M shares out so market cap is over $4ooM and rising as i see it trade at $35 now. However, vol is very very small so it doesn't mean much.
ORTX.OB closed at $27 which is about the same market cup for Protalix as reflected by Biocell's price in Tel-Aviv.
Here is the link
http://biz.yahoo.com/prnews/070103/clw058.html?.v=78
Protalix-Orthodontix merger is done. Will be interesting to watch how the "new" stock ORTX.
average numbers of posts per day in
2007: 59
ENCY is taking another fall
http://yahoo.reuters.com/news/articlehybrid.aspx?storyID=urn:newsml:reuters.com:20061228:MTFH63392_2...
I know Protalix from back when they were called Metabogal. At the moment i am holding Biocell and Marathon and waiting to see how OTIX will behave after the merge. Looks like it has some way down for now.
http://biz.yahoo.com/prnews/061219/cltu113.html?.v=10
Press Release Source: Orthodontix, Inc.
Orthodontix Announces Completion of Actions Required for Protalix Merger
Tuesday December 19, 2:31 pm ET
MIAMI, Dec. 19 /PRNewswire-FirstCall/ -- Orthodontix, Inc. (OTC Bulletin Board: OTIX - News; "Orthodontix") announced today that it is completing all corporate actions required to consummate the proposed merger of its wholly-owned subsidiary Protalix Acquisition Co., Ltd. with Protalix Ltd., a privately-held Israeli biotechnology company. The merger is expected to be completed by December 31, 2006.
ADVERTISEMENT
In connection with the merger, Orthodontix filed a preliminary information statement with the Securities and Exchange Commission on December 15, 2006 to announce to shareholders that Orthodontix is changing its name to Protalix BioTherapeutics, Inc. and is adopting a new incentive stock plan. In addition, Orthodontix will effect a reverse stock split of one share for every ten shares currently outstanding and authorized. The name change and the reverse stock split will become effective upon filing articles of amendment to Orthodontix's articles of incorporation prior to the merger. If the merger is not consummated, Orthodontix will not effect the name change.
On December 18, Orthodontix filed notice with the Securities and Exchange Commission of the change in directors that will occur upon consummation of the merger. Dr. Phillip Frost, former Chairman and Chief Executive Officer of IVAX Corporation and current Vice Chairman of Teva Pharmaceutical Industries Ltd., and Dr. Jane Hsiao, former Vice Chairman of IVAX Corporation, will join the board of Orthodontix, along with Eli Hurvitz, Chairman of the Board of Teva Pharmaceuticals and Protalix Ltd., and Dr. David Aviezer, Chief Executive Officer of Protalix Ltd. Mr. Hurvitz will serve as the Chairman of the Board of the merged company, and Dr. Aviezer will serve as its Chief Executive Officer. All of Orthodontix's current officers and directors will resign on the date of the merger. Glenn L. Halpryn, CEO of Orthodontix, stated that Protalix has an excellent management team and a very experienced and prominent Board of Directors with business and technical experience to guide the merged company through the anticipated Phase III clinical trial of its lead compound for the treatment of Gaucher Disease.
When the merger is consummated, the former shareholders of Protalix will receive shares of the merged company's common stock in exchange for all of their ordinary shares of Protalix Ltd. The currently outstanding shares of common stock of Orthodontix will represent a less than 1% interest in the combined company. Approximately 15% of the outstanding shares of the merged company's common stock on a fully diluted basis immediately after the closing of the merger will be held by certain recent investors in Protalix Ltd., including Dr. Frost and Glenn Halpryn. The merged company will assume all of Protalix Ltd.'s outstanding warrants and options, including all outstanding options issued under its employee stock option plan. The assumed options and warrants will represent approximately 21% of the merged company's outstanding common stock on a fully diluted basis after the merger. In addition, it is contemplated that following the merger, the merged company will issue to Dr. Frost and/or certain of his associates or affiliated entities that have or will provide services to the merged company, stock options that are exercisable into 3.5%, of the outstanding common stock on a fully-diluted basis.
TARO
Thanks for the link (got it in Hebrew).
I agree with the writer and wait for some new blood and money to get in to TARO.
genisi
TARO-
They will be delisted tomorrow.
http://biz.yahoo.com/pz/061212/110314.html
TARO-
This unresolved issue is known for long time and only god knows why they did not file on time. This was why the stock dropped under $10. I don't know why but some trusted analyst here were not taking this issue so hard. Perhaps they are sure that TARO will get over this hurdle or the buyers don't consider it so much. The stock might indeed take a fall but eventually will bounce before a takeover. Personally, i am taking my chances with TARO but with 60% of my position (sold 40% yesterday).
TARO-update
Company did not file a report (the "2005 Form 20-F")on time (dead end was last night. Fear for delisting is probably the main reason for today's drop.
I'm happy for you. I may take some profit say one third tonight and wait with the rest.
If it is of your interest, i will post when more news will come.
Israel is a small place and news fly fast...
TARO-
Usually i don't trust analyst nor newspaper reporters but i did buy TARO as it went below $10 because this time the rumour came from people i know and trust their knowledge and understanding (especially with value). They talk about price target of $17 if TARO will be bought but say that it is a buy for $10 anyway even if the deal with Ofer fund will not take place.
Sorry, that is all i know.
NUVO
I have been reading your post on NUVO and along with the dear price i stayed out, I thank you for that. Perhaps they are more interesting under $4 with rNAPc2, NU206 and NU172.
It appears those analysts were right regarding TARO:
http://yahoo.reuters.com/news/articlehybrid.aspx?storyID=urn:newsml:reuters.com:20061211:MTFH01831_2...
I was lucky to listen and got in under $9 hoping the company will be sold for $17.
NUVO-
Nuvelo and Bayer Healthcare Announce Phase 3 Trials of Alfimeprase in Patients With Acute Peripheral Arterial Occlusion and Catheter Occlusion Did Not Meet Primary Endpoints.Conference Call
Scheduled to start Mon, Dec 11, 2006, 8:30 am Eastern.
Stock down 82% premarket.
FWIW, Some analysts here in Israel like TARO under 10$ and bet it will be bought soon.
ONXX-
"It's not so surprising imo..everyone seems to fail in advanced melanoma..maybe THE most chemoresistant malignancy"
So why the huge drop?
Nexavar, ONXX
The stock gets some 30% haircut. looks like melanoma indication had high expectations.
keep us informed if you please.
Is there a way to find out if there were few heavy players who moved the stock today?
DYAX
very strange up&down with large vol today. no idea what is behind this.
One more pro- insiders were buying between 2.94$ to 3.15$ a share, for 140,100$ and 0 sales. Although it is not large some of money it give some positive angle.
I know the answers but i'll pass since i sent that article.
Regarding aesthetic/cosmetics, I usually pass those too.
I was also out for some time and got in today at the Tel-Aviv stock market. I think it is a good buy even if all those fears will hold the price for a while.
Best, genisi.
TEVA-
And the stock keeps going down in Tel-Aviv as well as here.
Is it the fear that TEVA will not grow? The new CEO?
This looks like good news for PGNX.
XL-999:
Dew, can you please explain what do you mean by "dirty drugs"? Do you consider Nexavar or Sutent also in this category?
The CEO of TEVA left (resign) today and the stock went down some 4% at Tel-Aviv market. it is also -3% Pre market at WS. No coment from the company yet.
Praveen, Thaks for digging the paper for me.
genisi
Re: Median values not indicative of hazard ratio
Thanks a lot for the educated explanation.
genisi
WYE- Torisel
But is it safe to assume that these median overall survival results are good indicators for the hazard ratio?
How long from NDA to marketing?
T.I.A
genisi
"a takeunder by GENZ"
Could you please explain for a layman why "investors ought to be worried about such an outcome"?
FDA Statement on Coronary Drug-Eluting Stents
http://pharmalive.com/news/index.cfm?articleID=373031&categoryid=9&newsletter=1
ROCKVILLE, Md., Sept. 14, 2006-FDA is providing the following information in response to inquiries asking for the agency’s position on adverse events related to coronary drug-eluting stents (DES). This information describes our position at this time and does not represent new agency policy.
FDA has been closely monitoring DES since they came to the United States market in 2003 and 2004 – and will continue to do so.
We are aware of recent data suggesting a small but significant increase in the rate of death and myocardial infarction (heart attack) possibly due to stent thrombosis (a blood clot in the stent) in patients treated with DES. The specific studies that have prompted recent media inquiries are the BASKET-LATE study (presented at the March 2006 American College of Cardiology Scientific Sessions in Atlanta, Ga.) and more recently, the Camenzind meta-analysis (presented at the September 2006 European Society of Cardiology Annual Meeting/World Congress of Cardiology Meeting in Barcelona, Spain). The small but significant increase in the rate of death and myocardial infarction observed in these studies was noted in patients followed 18 months to 3 years after stent implantation.
While the studies presented at the Atlanta and Barcelona meetings have raised important questions, the data we currently have do not allow us to fully characterize the mechanism, risks, and incidence of DES thrombosis. A more formal evaluation of the data in these studies is necessary, and any conclusions are dependent upon a thorough peer review. FDA intends to more formally evaluate the studies presented in Atlanta and Barcelona.
Stent thrombosis in patients who receive DES is a primary area of interest for the agency because of the potential for serious adverse outcomes—even though stent thrombosis occurs at low rates. Over the past two months, the agency has met with both manufacturers of the FDA-approved approved DES to discuss any information and perspectives they have that may be pertinent to this issue. In assessing the risk of stent thrombosis, we remain keenly interested in the long-term follow-up of patients enrolled in the original pivotal DES randomized trials as well as those in the more complex patient and lesion subsets (for example, patients with diabetes; acute myocardial infarction or multiple vessel disease; or lesions involving arterial bifurcations, the left main coronary artery, and long arterial segments) who are currently being treated in “real world” randomized and registry studies.
FDA also continues to closely evaluate information related to the duration of treatment with clopidogrel (Plavix), a drug used in combination with aspirin to reduce/prevent clotting in DES patients. Although the duration of clopidogrel appeared to be adequate for the selected patients in the original clinical trials conducted to support FDA approval, the agency recognizes that the optimal duration of clopidogrel in more complex patients has not been defined. The recommended duration of clopidogrel administration and patient compliance with the prescribed regimen are likely interrelated with patient and anatomical factors that are associated with DES thrombosis. Additional clinical data are likely needed to reach conclusions regarding the optimal antiplatelet therapy regimen for DES patients.
FDA will convene a public meeting of the Circulatory System Devices Advisory Panel by the end of the year in an effort to improve our knowledge regarding the incidence and timing of stent thrombosis as well as the appropriate duration of clopidogrel use in patients who receive DES. This Panel of outside experts will assist the agency in the review and analysis of the available scientific data and provide recommendations for appropriate actions to address this issue, such as possible changes to device labeling or the need for additional clinical studies. An announcement of this meeting will appear on FDA’s web site, www.fda.gov/cdrh.
At this time, FDA believes that coronary DES remain safe and effective when used in patients having clinical and coronary anatomic features similar to those treated in the pivotal trials conducted by the manufacturers for FDA approval. The approved indications are:
The CYPHER Sirolimus-eluting Coronary Stent is indicated for improving coronary luminal diameter in patients with symptomatic ischemic disease due to discrete de novo lesions of length < 30 mm in native coronary arteries with reference vessel diameter of >2.5 mm to <3.5 mm.
The TAXUS Express Paclitaxel-Eluting Coronary Stent System is indicated for improving luminal diameter for the treatment of de novo lesions <28 mm in length in native coronary arteries >2.5 to <3.75 mm in diameter.
For more information, see http://www.fda.gov/cdrh/pdf2/P020026.html and http://www.fda.gov/cdrh/pdf3/P030025.html.
For thousands of patients each year, these devices have resulted in a significant reduction in the need of second procedures to treat restenosis. The FDA will continue to carefully evaluate all DES data in an attempt to maximize the benefits and minimize the risks for patients undergoing this therapy for treatment of their coronary artery disease.
To summarize:
FDA has been monitoring coronary drug-eluting stents closely since they came on the U.S. market in 2003 and 2004, and will continue to do so. New data were released recently that suggest a small but significant increased risk of stent thrombosis in patients who have drug-eluting stents. The agency is keenly interested in this issue because of the potential for serious harm to patients—even though stent thrombosis occurs at low rates. While the new data are of interest to FDA and raise important questions, we do not have enough information yet to draw conclusions. It’s unclear, for example, what causes drug-eluting stent thrombosis, how often it occurs, under what circumstances it occurs, or what the risk of occurrence is in a given patient. To better understand this issue, FDA met with the two manufacturers of these products in recent months to discuss any information they might have pertaining to this issue and get their perspective. In addition, we plan to convene a public panel meeting of outside scientific experts in the near future to assist us in a thorough review of all the data and make recommendations about what actions may be appropriate, such as possible labeling changes or additional studies. At this time, FDA believes that coronary drug-eluting stents remain safe and effective when used for the FDA-approved indications. These devices have significantly reduced the need for a second surgery to treat restenosis for thousands of patients each year.
GlycoFi:
Genetic transformation is, in most cases, very stable and inherted for many generations. It is true in yeast, mice and livestock. So the transformed yeast can be used safely for proper glycosylation of forein proteins. However, I am not too sure it will provide a bona fide protein. There are other modifications that may defect the function of a protein (acetylation, methylation etc.).
CVTX-Have you not changed your mind about them yet? They kept going down since you post about them.
Did you see what goes on ? 40% up on the good opinion from Europa.